SKU: T127  / 
    CAS Number: 173903-47-4

    Tizoxanide

    $215.25 - $1,638.00

    Tizoxanide is a metabolite of Nitazoxanide. It is an antiparasitic agent that can inhibit anaerobic bacteria, protozoa, and a range of viruses including hepatitis B and C.

     

    Mechanism of ActionTizoxanide is the active metaboliite Nitazoxanide. This anthelmintic agent is able to inhibit viral replication, including hepatitis B and C viruses.
    SpectrumTizoxanide is active against anaerobic bacteria, protozoa, and a range of viruses.
    Microbiology ApplicationsTizoxanide is effective against parasites (Leishmania mexicana, Trypanosoma cruzi), influenza A, hepatitis B and C.
    Eukaryotic Cell Culture ApplicationsThe protein binding ability of Tizoxanide in goat plasma, albumin, and alpha-1-acid-glycoprotein were investigated in vitro. The protein binding percentage (at4 ug/ml) was > 95% in plasma and albumin solution, compared to only 49% in alpha-1-acid-glycoprotein solution, likely due to its acidic property (Zaho et al, 2010). The concept of 'drug repositioning'- using known molecules for new indications, was used to screen 1600 compounds in a high-throughput screening approach using glucose-deprived multicellular tumor spheroids (MCTS) to identify compounds that target dormant cancer cells in solid tumors. Since cancer cells in low glucose environments depend on oxidative phosphorylation rather than solely on glycolysis, continuous exposure is needed, and of the five compounds with MCTS activity, Nitazoxanide is the only one that reaches high plasma concentrations. Nitazoxanide activated the AMPK pathway and down-regulated c-Myc, mTOR, and Wnt signaling, suggesting it could be a candidate for anti-cancer applications (Senkowski W et al, 2015).
    Molecular FormulaC10H7N3O4S
    ReferencesKorba BE et al (2008) Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral. Res. 77(1):56-63 Senkowski W et al (2015) Three-dimentional cell culture-based screening identifies the anthelmintic drug Nitazoxanide as a candidate for treatment of colorectal cancer. Mol Cancer Ther 14(6):1504-1516 Zhao Z et al (2010) the pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro. J. Vet. Pharmacol. Ther. 33(2):147-153